RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
EpicentRx, Inc.
Eli Lilly and Company
Pfizer
Canadian Cancer Trials Group
Gilead Sciences
Pfizer
INSYS Therapeutics Inc